BlackRock, Inc. 13D and 13G filings for Black Diamond Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Black Diamond Therapeutics, Inc. BDTX |
BlackRock Inc. BLK |
3,497,766 6.200% |
0 (Unchanged) |
Filing |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | Black Diamond Therapeutics, Inc. BDTX |
BlackRock Inc. BLK |
3,497,766 6.200% |
2,225,654 (+174.96%) |
Filing |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Black Diamond Therapeutics, Inc. BDTX |
BlackRock Inc. BLK |
1,272,112 3.500% |
-976,355 (-43.42%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Black Diamond Therapeutics, Inc. BDTX |
BlackRock Inc. BLK |
2,248,467 6.200% |
2,248,467 (New Position) |
Filing |